![Landing Page Header (2) (1)](https://www.amadorbioscience.com/hs-fs/hubfs/Web/Landing%20Pages/Landing%20Page%20Header%20(2)%20(1).png?width=960&height=640&name=Landing%20Page%20Header%20(2)%20(1).png)
Blog
Welcome to our NEW blog where you can explore insightful articles on the latest advances and trends for next-gen drug development.
![How can precision dosing be integrated into model-informed drug development](https://www.amadorbioscience.com/hs-fs/hubfs/MIDD-1.png?width=320&height=240&name=MIDD-1.png)
![PopPK Modeling of Rivoceranib in Healthy Subjects and Cancer Patients](https://www.amadorbioscience.com/hs-fs/hubfs/640%20%281%29.webp?width=320&height=240&name=640%20%281%29.webp)
![PopPK and PD Modeling of NGM707, an ILT2/ILT4 Dual Antagonist Antibody in Patients with Advanced or Metastatic Solid Tumors](https://www.amadorbioscience.com/hs-fs/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-03-3.jpg?width=320&height=240&name=%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-03-3.jpg)
![Food and Co-administration of Acid Reducing Agents (ARAs) Have No Clinically Significant Effect on the Pharmacokinetics of Etrumadenant, a Novel Dual Adenosine Receptor Antagonist](https://www.amadorbioscience.com/hs-fs/hubfs/linkedin-Insights-05.jpg?width=320&height=240&name=linkedin-Insights-05.jpg)
![Population Pharmacokinetic Modeling of Camrelizumab in Patients with Various Cancer Types, Including Advanced Hepatocellular Carcinoma](https://www.amadorbioscience.com/hs-fs/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-07-1.jpg?width=320&height=240&name=%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-07-1.jpg)
![PopPK Modeling of NGM438 in Advanced/Metastatic Solid Tumor Patients](https://www.amadorbioscience.com/hs-fs/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-02-3.jpg?width=320&height=240&name=%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-02-3.jpg)
![Clinical Pharmacology Considerations for ADC Guidance for Industry](https://www.amadorbioscience.com/hs-fs/hubfs/ADC%20guidance.png?width=320&height=240&name=ADC%20guidance.png)
![Pediatric Dose Simulations](https://www.amadorbioscience.com/hs-fs/hubfs/%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-06.jpg?width=320&height=240&name=%E5%90%8C%E6%AD%A5LinkedIn%E5%B0%BA%E5%AF%B8-06.jpg)
![Novel ADC PK Assays Revolutionize Targeted Therapy Analysis](https://www.amadorbioscience.com/hs-fs/hubfs/IMG_1033-02.jpg?width=320&height=240&name=IMG_1033-02.jpg)
![Evaluating ADA Response Essential for Biologics](https://www.amadorbioscience.com/hs-fs/hubfs/111-1.jpg?width=320&height=240&name=111-1.jpg)
![Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysis](https://www.amadorbioscience.com/hs-fs/hubfs/1668610802356.jpeg?width=320&height=240&name=1668610802356.jpeg)
![Remote audits: a CRO virtual reality-what lessons have been learned in a time of unexpected isolation](https://www.amadorbioscience.com/hs-fs/hubfs/1669812601441.jpeg?width=320&height=240&name=1669812601441.jpeg)
![【Webinar】 Quantitative Bio-analysis of ADCs using Mass Spectrometry (with video)](https://www.amadorbioscience.com/hs-fs/hubfs/LinkedIn%20webinar-02.jpg?width=320&height=240&name=LinkedIn%20webinar-02.jpg)
![Combination therapies and predicting regimens](https://www.amadorbioscience.com/hs-fs/hubfs/linkedin-Insights-01.jpg?width=320&height=240&name=linkedin-Insights-01.jpg)
![Where Science Meets Strategy: Elevate Your Drug Development Program with Clinical Pharmacology](https://www.amadorbioscience.com/hs-fs/hubfs/image-cp-1-1.jpg?width=320&height=240&name=image-cp-1-1.jpg)
![Differences in levels ofphosphatidylinositols in healthy and stable Coronary Artery Disease subjects revealed by HILIC-MRM method with SERRF normalization](https://www.amadorbioscience.com/hs-fs/hubfs/1668085202329.jpeg?width=320&height=240&name=1668085202329.jpeg)
![【Webinar】 Model Informed Drug Development: Application to Project Optimus (with video)](https://www.amadorbioscience.com/hs-fs/hubfs/%E5%9B%BE%E5%83%8F%20%281%29.png?width=320&height=240&name=%E5%9B%BE%E5%83%8F%20%281%29.png)
![Project Optimus: Drug Development Expertise Fits New FDA Guidance Targeting Cancer Therapeutics](https://www.amadorbioscience.com/hs-fs/hubfs/Copy%20of%20News%20-%20Featured%20Images.png?width=320&height=240&name=Copy%20of%20News%20-%20Featured%20Images.png)
![【Webinar】 Bioanalytical Strategies for Gene Therapy: Bioanalysis of Lipid Nanoparticles Encapsulated Antisense Oligonucleotides (with video)](https://www.amadorbioscience.com/hs-fs/hubfs/LinkedIn%20webinar-05.jpg?width=320&height=240&name=LinkedIn%20webinar-05.jpg)
![Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation](https://www.amadorbioscience.com/hs-fs/hubfs/1675254601459.jpeg?width=320&height=240&name=1675254601459.jpeg)
![Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation](https://www.amadorbioscience.com/hs-fs/hubfs/1675254601459%20%281%29.jpeg?width=320&height=240&name=1675254601459%20%281%29.jpeg)
Sign up to receive our latest updates via email!
Let's stay in touch.
Welcome to our NEW blog where you can explore insightful articles on the latest advances and trends for next-gen drug development.
Let's stay in touch.
By signing up, you agree to the Privacy Policy.